Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats

Drug and Alcohol Dependence

Volumn 153, Issue , 2015, Pages 29-36

  Miller, M L ^a   Aarde, S M ^a   Moreno, A Y ^a   Creehan, K M ^a   Janda, K D ^a   Taffe, M A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Active vaccination; Drug addiction; Immunopharmacotherapy; Methamphetamine; Self administration

Indexed keywords

BIOLOGICAL PRODUCT; DRUGS USED IN THE TREATMENT OF ADDICTION; KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; METHAMPHETAMINE; METHAMPHETAMINE HAPTEN KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; UNCLASSIFIED DRUG; VACCINE; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN;

ACTIVE VACCINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DOSE SUBSTITUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SELF ADMINISTRATION; INTRAVENOUS SELF ADMINISTRATION; MALE; METHAMPHETAMINE BLOOD LEVEL; METHAMPHETAMINE DEPENDENCE; NONHUMAN; NUMBER OF INFUSION; OUTCOME ASSESSMENT; PARAMETERS; POST HOC ANALYSIS; PRIORITY JOURNAL; RAT; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BEHAVIOR, ADDICTIVE; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; PSYCHOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

RATTUS;

ANIMALS; BEHAVIOR, ADDICTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOCYANIN; INFUSIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; TREATMENT OUTCOME; VACCINATION; VACCINES;

EID: 84937643683     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.06.014     Document Type: Article

References (56)

1. Aarde S.M., Angrish D., Barlow D.J., Wright M.J., Vandewater S.A., Creehan K.M., Houseknecht K.L., Dickerson T.J., Taffe M.A. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict. Biol. 2013, 18:786-799.
2. Aarde S.M., Huang P.K., Creehan K.M., Dickerson T.J., Taffe M.A. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 2013, 71:130-140.
3. Aarde S.M., Huang P.K., Dickerson T.J., Taffe M.A. Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats. Psychopharmacology (Berl.) 2015, 232:1867-1877.
4. Aarde S.M., Miller M.L., Creehan K.M., Vandewater S.A., Taffe M.A. One day access to a running wheel reduces self-administration of d-methamphetamine. MDMA and methylone. Drug Alcohol Depend. 2015, 151:151-158.
5. Anthony J.C., Warner L.A., Kessler R.C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the national comorbidity survey. Exp. Clin. Pyschopharmacol. 1994, 2:244-268.
6. Byrnes-Blake K.A., Carroll F.I., Abraham P., Owens S.M. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int. Immunopharmacol. 2001, 1:329-338.
7. Caine S.B., Koob G.F. Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J. Pharmacol. Exp. Ther. 1994, 270:209-218.
8. Carrera M.R., Ashley J.A., Hoffman T.Z., Isomura S., Wirsching P., Koob G.F., Janda K.D. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg. Med. Chem. 2004, 12:563-570.
9. Carrera M.R., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378:727-730.
10. Carrera M.R., Ashley J.A., Wirsching P., Koob G.F., Janda K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1988-1992.
11. Carrera M.R., Ashley J.A., Zhou B., Wirsching P., Koob G.F., Janda K.D. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6202-6206.
12. Cerny E.H., Levy R., Mauel J., Mpandi M., Mutter M., Henzelin-Nkubana C., Patiny L., Tuchscherer G., Cerny T. Preclinical development of a vaccine 'against smoking'. Onkologie 2002, 25:406-411.
13. Constantine N.A., Jerman P., Huang A.X. California parents' preferences and beliefs regarding school-based sex education policy. Perspect. Sex Reprod. Health 2007, 39:167-175.
14. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., Bangala Y., Guessous I., Muller P., Willers J., Maurer P., Bachmann M.F., Cerny T. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 2008, 3:e2547.
15. Creehan K.M., Vandewater S.A., Taffe M.A. Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 2015, 92:90-97.
16. de Villiers S.H., Lindblom N., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn. Schmiedebergs Arch. Pharmacol. 2004, 370:299-304.
17. Duryee M.J., Bevins R.A., Reichel C.M., Murray J.E., Dong Y., Thiele G.M., Sanderson S.D. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009, 27:2981-2988.
18. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K., Botka A.J., French T.L., Thompson T.L., Schad V.C., Greenstein J.L., Gefter M.L., Exley M.A., Swain P.A., Briner T.J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 1996, 2:1129-1132.
19. Gentry W.B., Ruedi-Bettschen D., Owens S.M. Development of active and passive human vaccines to treat methamphetamine addiction. Hum. Vaccin. 2009, 5:206-213.
20. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 2010, 67:59-65.
21. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., Tashkin D.P., Reus V.I., Akhavain R.C., Fahim R.E., Kessler P.D., Niknian M., Kalnik M.W., Rennard S.I. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 2011, 89:392-399.
22. Hendrickson H., Laurenzana E., Owens S.M. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J. 2006, 8:E709-E717.
23. Hoogsteder P.H., Kotz D., van Spiegel P.I., Viechtbauer W., van Schayck O.C. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction 2014, 109:1252-1259.
24. Janda K.D., Treweek J.B. Vaccines targeting drugs of abuse: is the glass half-empty or half-full?. Nat. Rev. Immunol. 2012, 12:67-72.
25. Kantak K.M., Collins S.L., Bond J., Fox B.S. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl.) 2001, 153:334-340.
26. Kantak K.M., Collins S.L., Lipman E.G., Bond J., Giovanoni K., Fox B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl.) 2000, 148:251-262.
27. Karila L., Weinstein A., Aubin H.J., Benyamina A., Reynaud M., Batki S.L. Pharmacological approaches to methamphetamine dependence: a focused review. Br. J. Clin. Pharmacol. 2010, 69:578-592.
28. Keyler D.E., Hieda Y., St Peter J., Pentel P.R. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob. Res. 1999, 1:241-249.
29. Keyler D.E., Roiko S.A., Benlhabib E., LeSage M.G., St Peter J.V., Stewart S., Fuller S., Le C.T., Pentel P.R. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab. Dispos. 2005, 33:1056-1061.
30. Koob G.F., Le H.T., Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci. Lett. 1987, 79:315-320.
31. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S., Shields J., Jack L., Fox B. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20:1196-1204.
32. LeSage M.G., Keyler D.E., Hieda Y., Collins G., Burroughs D., Le C., Pentel P.R. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl.) 2006, 184:409-416.
33. LeSage M.G., Keyler D.E., Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. 2006, 8:E65-E75.
34. Lindblom N., de Villiers S.H., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002, 69:254-260.
35. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., Kosten T.R. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 2009, 66:1116-1123.
36. Miller M.L., Moreno A.Y., Aarde S.M., Creehan K.M., Vandewater S.A., Vaillancourt B.D., Wright M.J., Janda K.D., Taffe M.A. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol. Psychiatry 2013, 73:721-728.
37. Miller M.L., Vaillancourt B.D., Wright M.J., Aarde S.M., Vandewater S.A., Creehan K.M., Taffe M.A. Reciprocal inhibitory effects of intravenous d-methamphetamine self-administration and wheel activity in rats. Drug Alcohol Depend. 2012, 121:90-96.
38. Moreno A.Y., Janda K.D. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav. 2009, 92:199-205.
39. Moreno A.Y., Mayorov A.V., Janda K.D. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J. Am. Chem. Soc. 2011, 133:6587-6595.
40. Pentel P.R., Malin D.H., Ennifar S., Hieda Y., Keyler D.E., Lake J.R., Milstein J.R., Basham L.E., Coy R.T., Moon J.W., Naso R., Fattom A. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 2000, 65:191-198.
41. Pickens R., Thompson T. Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size. J. Pharmacol. Exp. Ther. 1968, 161:122-129.
42. Pitas G., Laurenzana E.M., Williams D.K., Owens S.M., Gentry W.B. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab. Dispos. 2006, 34:906-912.
43. Pravetoni M., Keyler D.E., Raleigh M.D., Harris A.C., Lesage M.G., Mattson C.K., Pettersson S., Pentel P.R. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem. Pharmacol. 2011, 81:1164-1170.
44. Roiko S.A., Harris A.C., Keyler D.E., Lesage M.G., Zhang Y., Pentel P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J. Pharmacol. Exp. Ther. 2008, 325:985-993.
45. Roll J.M., Petry N.M., Stitzer M.L., Brecht M.L., Peirce J.M., McCann M.J., Blaine J., MacDonald M., DiMaria J., Lucero L., Kellogg S. Contingency management for the treatment of methamphetamine use disorders. Am. J. Psychiatry 2006, 163:1993-1999.
46. Ruedi-Bettschen D., Wood S.L., Gunnell M.G., West C.M., Pidaparthi R.R., Carroll F.I., Blough B.E., Owens S.M. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 2013, 31:4596-4602.
47. SAMHSA Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings 2010, SAMHSA, NSDUH, Rockville, MD.
48. Schramm-Sapyta N.L., Walker Q.D., Caster J.M., Levin E.D., Kuhn C.M. Are adolescents more vulnerable to drug addiction than adults? Evidence from animal models. Psychopharmacology (Berl.) 2009, 206:1-21.
49. Shen X.Y., Kosten T.A., Lopez A.Y., Kinsey B.M., Kosten T.R., Orson F.M. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend. 2013, 129:41-48.
50. Shi L., Sings H.L., Bryan J.T., Wang B., Wang Y., Mach H., Kosinski M., Washabaugh M.W., Sitrin R., Barr E. GARDASIL: prophylactic human papillomavirus vaccine development - from bench top to bed-side. Clin. Pharmacol. Ther. 2007, 81:259-264.
51. Smith M.A., Witte M.A. The effects of exercise on cocaine self-administration, food-maintained responding, and locomotor activity in female rats: importance of the temporal relationship between physical activity and initial drug exposure. Exp. Clin. Psychopharmacol. 2012, 20:437-446.
52. Vocci F.J., Appel N.M. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007, 102(Suppl. 1):96-106.
53. Wee S., Hicks M.J., De B.P., Rosenberg J.B., Moreno A.Y., Kaminsky S.M., Janda K.D., Crystal R.G., Koob G.F. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 2012, 37:1083-1091.
54. Wilson M.C., Hitomi M., Schuster C.R. Psychomotor stimulant self administration as a function of dosage per injection in the rhesus monkey. Psychopharmacologia 1971, 22:271-281.
55. Wilson M.C., Schuster C.R. The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey. Psychopharmacologia 1972, 26:115-126.
56. Young M.J., Sisti D.A., Rimon-Greenspan H., Schwartz J.L., Caplan A.L. Immune to addiction: the ethical dimensions of vaccines against substance abuse. Nat. Immunol. 2012, 13:521-524.